EVMN8:30 AMEvommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous UrticariaTrial Results • Phase 2Top-line results Mon, Jun 29, 2026, 8:30 AM EDTGevommune.com
EVMN4:05 PMEvommune Reports First Quarter 2026 Financial Results and Provides Business Highlightsevommune.com